Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | GCGR | P47871 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644163 | 0.83 | APOBEC3G (0.56) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2644453 | 0.81 | APOBEC3G (0.58) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2648027 | 0.80 | APOBEC3G (0.57) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2644074 | 0.78 | APOBEC3G (0.65) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2644079 | 0.75 | APOBEC3G (0.61) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2644097 | 0.74 | GCGR (0.55) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2643566 | 0.74 | GCGR (0.55) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2643107 | 0.74 | GCGR (0.55) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2643240 | 0.74 | GCGR (0.55) | APOBEC3GGCGRHPGDRXFP1BRAF | |
| SCHEMBL2643253 | 0.73 | GCGR (0.54) | APOBEC3GGCGRHPGDRXFP1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196106-B2 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | MERCK & CO., INC (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040097552-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097552-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | GLP1R, GPR119, GCGR | APOBEC3G 4604/4885GCGR 3/4885HPGD 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.